Albert Bourla (Evan Vucci, AP Images)
Amid safety concerns, FDA grants two new JAK approvals — but with added warnings and a key label change
After a post-marketing trial for Pfizer’s Xeljanz turned up concerning safety results at the beginning of the year, thwarting the whole JAK class, the FDA …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
